产品
编 号：F745217
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1443004-15-6
产品详情
生物活性：
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice.
体内研究：
Firivumab (CT-P22; CT120; 7.5-30 mg/kg; 腹腔给药; 感染后 24 小时) 在 >15 mg/kg 处理组中对 H1N1 病毒显示 100% 的保护，在 7.5 mg/kg 处理组中显示 70% 的保护。Firivumab (添加 7.5 mg/kg Firivumab 和 7.5 mg/kg CT149) 在 A/California/04/09 (H1N1) 处理的小鼠中表现出全面保护。Animal Model:Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)
Dosage:7.5, 15, 30 mg/kg
Administration:IP; Twenty-four hours post-infection
Result:Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group.Could not protect mice from H3N2 infection.
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice.
体内研究：
Firivumab (CT-P22; CT120; 7.5-30 mg/kg; 腹腔给药; 感染后 24 小时) 在 >15 mg/kg 处理组中对 H1N1 病毒显示 100% 的保护，在 7.5 mg/kg 处理组中显示 70% 的保护。Firivumab (添加 7.5 mg/kg Firivumab 和 7.5 mg/kg CT149) 在 A/California/04/09 (H1N1) 处理的小鼠中表现出全面保护。Animal Model:Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)
Dosage:7.5, 15, 30 mg/kg
Administration:IP; Twenty-four hours post-infection
Result:Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group.Could not protect mice from H3N2 infection.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备